vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Northfield Bancorp, Inc. (NFBK). Click either name above to swap in a different company.
Northfield Bancorp, Inc. is the larger business by last-quarter revenue ($41.3M vs $21.9M, roughly 1.9× Cue Biopharma, Inc.). Cue Biopharma, Inc. runs the higher net margin — 7.2% vs -1545.5%, a 1552.7% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 12.7%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 15.0%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Northfield Bancorp, Inc. is a regional bank holding company based in the United States, operating primarily across the U.S. Northeast region. It provides a full range of personal and commercial banking services including deposit accounts, mortgage loans, commercial lending, and wealth management solutions for retail consumers, small to medium-sized businesses and local community clients.
CUE vs NFBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $41.3M |
| Net Profit | $1.6M | $-27.4M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | -1263.3% |
| Net Margin | 7.2% | -1545.5% |
| Revenue YoY | 1292.3% | 12.7% |
| Net Profit YoY | 116.7% | -343.6% |
| EPS (diluted) | $0.05 | $-0.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $41.3M | ||
| Q3 25 | $2.1M | $39.2M | ||
| Q2 25 | $3.0M | $38.9M | ||
| Q1 25 | $421.0K | $34.8M | ||
| Q4 24 | $1.6M | $36.7M | ||
| Q3 24 | $3.3M | $31.8M | ||
| Q2 24 | $2.7M | $31.5M | ||
| Q1 24 | $1.7M | $31.3M |
| Q4 25 | $1.6M | $-27.4M | ||
| Q3 25 | $-7.4M | $10.8M | ||
| Q2 25 | $-8.5M | $9.6M | ||
| Q1 25 | $-12.3M | $7.9M | ||
| Q4 24 | — | $11.3M | ||
| Q3 24 | $-8.7M | $6.5M | ||
| Q2 24 | $-10.2M | $6.0M | ||
| Q1 24 | $-12.3M | $6.2M |
| Q4 25 | 9.0% | -1263.3% | ||
| Q3 25 | -353.4% | 37.7% | ||
| Q2 25 | -292.3% | 35.6% | ||
| Q1 25 | -2921.4% | 31.0% | ||
| Q4 24 | — | 38.0% | ||
| Q3 24 | -264.2% | 27.9% | ||
| Q2 24 | -390.6% | 29.1% | ||
| Q1 24 | -737.8% | 27.2% |
| Q4 25 | 7.2% | -1545.5% | ||
| Q3 25 | -346.6% | 27.4% | ||
| Q2 25 | -287.1% | 24.6% | ||
| Q1 25 | -2911.4% | 22.6% | ||
| Q4 24 | — | 30.7% | ||
| Q3 24 | -259.6% | 20.5% | ||
| Q2 24 | -382.7% | 18.9% | ||
| Q1 24 | -719.1% | 19.9% |
| Q4 25 | $0.05 | $-0.68 | ||
| Q3 25 | $-0.07 | $0.27 | ||
| Q2 25 | $-0.09 | $0.24 | ||
| Q1 25 | $-0.17 | $0.19 | ||
| Q4 24 | — | $0.27 | ||
| Q3 24 | $-0.17 | $0.16 | ||
| Q2 24 | $-0.20 | $0.14 | ||
| Q1 24 | $-0.25 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $164.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $690.1M |
| Total Assets | $42.2M | $5.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $164.0M | ||
| Q3 25 | $11.7M | $131.7M | ||
| Q2 25 | $27.5M | $97.6M | ||
| Q1 25 | $13.1M | $101.7M | ||
| Q4 24 | $22.5M | $167.7M | ||
| Q3 24 | $32.4M | $232.9M | ||
| Q2 24 | $30.0M | $153.5M | ||
| Q1 24 | $41.0M | $238.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $666.4M | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $690.1M | ||
| Q3 25 | $13.2M | $719.6M | ||
| Q2 25 | $18.2M | $710.3M | ||
| Q1 25 | $6.6M | $711.1M | ||
| Q4 24 | $17.5M | $704.7M | ||
| Q3 24 | $25.4M | $699.6M | ||
| Q2 24 | $21.6M | $693.0M | ||
| Q1 24 | $30.0M | $698.4M |
| Q4 25 | $42.2M | $5.8B | ||
| Q3 25 | $31.6M | $5.7B | ||
| Q2 25 | $40.7M | $5.7B | ||
| Q1 25 | $22.3M | $5.7B | ||
| Q4 24 | $32.2M | $5.7B | ||
| Q3 24 | $44.8M | $5.7B | ||
| Q2 24 | $42.3M | $5.7B | ||
| Q1 24 | $54.0M | $5.9B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.95× | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $53.7M |
| Free Cash FlowOCF − Capex | — | $52.5M |
| FCF MarginFCF / Revenue | — | 127.1% |
| Capex IntensityCapex / Revenue | 0.0% | 2.8% |
| Cash ConversionOCF / Net Profit | -0.68× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $89.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $53.7M | ||
| Q3 25 | $-9.0M | $13.9M | ||
| Q2 25 | $-3.4M | $14.1M | ||
| Q1 25 | $-8.2M | $9.4M | ||
| Q4 24 | $-36.3M | $31.1M | ||
| Q3 24 | $-7.5M | $14.0M | ||
| Q2 24 | $-10.0M | $6.9M | ||
| Q1 24 | $-9.8M | $4.2M |
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | $-3.4M | $13.9M | ||
| Q1 25 | $-8.3M | $9.2M | ||
| Q4 24 | $-36.4M | $30.0M | ||
| Q3 24 | $-7.5M | $13.7M | ||
| Q2 24 | $-10.0M | $6.7M | ||
| Q1 24 | $-9.8M | $3.8M |
| Q4 25 | — | 127.1% | ||
| Q3 25 | — | 34.6% | ||
| Q2 25 | -116.5% | 35.7% | ||
| Q1 25 | -1976.7% | 26.3% | ||
| Q4 24 | -2309.3% | 81.6% | ||
| Q3 24 | -225.7% | 43.2% | ||
| Q2 24 | -376.2% | 21.1% | ||
| Q1 24 | -573.0% | 12.1% |
| Q4 25 | 0.0% | 2.8% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.9% | 0.6% | ||
| Q1 25 | 35.6% | 0.7% | ||
| Q4 24 | 4.2% | 3.1% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.4% | 0.8% | ||
| Q1 24 | 3.2% | 1.4% |
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | 1.29× | ||
| Q2 25 | — | 1.48× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 2.76× | ||
| Q3 24 | — | 2.14× | ||
| Q2 24 | — | 1.16× | ||
| Q1 24 | — | 0.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
NFBK
Segment breakdown not available.
